US 12,258,416 B1
Bispecific constructs for target and complement engagement
Nick Stub Laursen, Aarhus C (DK); Dennis Vestergaard Pedersen, Aarhus C (DK); Gregers Rom Andersen, Brabrand (DK); Steffen Thiel, Risskov (DK); Alessandra Zarantonello, Aarhus C (DK); Rasmus Kjeldsen Jensen, Aarhus C (DK); and Henrik Pedersen, Aarhus C (DK)
Assigned to Aarhus Universitet, Aarhus C (DK)
Filed by Aarhus Universitet, Aarhus C (DK)
Filed on Mar. 27, 2024, as Appl. No. 18/618,626.
Application 18/618,626 is a continuation of application No. 17/251,023, granted, now 12,110,321, previously published as PCT/EP2019/065206, filed on Jun. 11, 2019.
Claims priority of application No. 18176954 (EP), filed on Jun. 11, 2018.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 9/0019 (2013.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01)] 19 Claims
 
1. A polypeptide construct that comprises:
(a) a VHH domain that binds to human C1q complement factor; and
(b) a target binding moiety that binds to a target selected from the group consisting of:
a cancer-specific marker; a pathogenic marker; a tissue-specific marker; and an organ-specific marker,
wherein the target-binding moiety comprises a heavy chain constant region (CH), a heavy chain variable region (VH), a light chain constant region (CL), a light chain variable region (VL), a camelid VHH domain, or a cartilaginous fish VNAR domain, and wherein the polypeptide construct activates a classical complement system when the polypeptide construct is bound to a cell surface.